Paion Ag Aachen (PAIOF) 2.3200 $PAIOF PAION Grants Cosmo

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Paion Ag Aachen (PAIOF) 2.3200 $PAIOF

PAION Grants Cosmo Pharmaceuticals remimazolam License in the U.S. and Cosmo Becomes Largest Shareholder of PAION AG
BusinessWire - Fri Jun 24, 1:12PM CDT
--- PAION entitled to receive up to EUR 42.5 million in milestone payments and significant double-digit tiered royalties

The Anesthetic Effect Pipeline Review, H2 2015 - 16 Companies & 24 Drug Profiles
M2 - Thu Dec 17, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/25xt8p/anesthetic_effect) has announced the addition of the "Anesthetic Effect - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anesthetic Effect, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anesthetic Effect and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Drug Profiles - (lidocaine hydrochloride phenylephrine hydrochloride tropicamide) - (tetracaine hydrochloride oxymetazoline hydrochloride) - ABP-700 - ADV-6209 - alphaxalone - bupivacaine hydrochloride - carboetomidate - Gabafol - HSK-3486 - lidocaine hydrochloride ER - LT-1121 - LT-1123 - methoxycarbonyl carboetomidate - methoxycarbonyl etomidate - neosaxitoxin - PB-5109 - PHY-301 - propofol - propofol microemulsion - propofol-DM - remimazolam - remimazolam - Small Molecules to Inhibit NMDA Receptor for Anaesthesia - sugammadex sodium Companies Mentioned - Advicenne Pharma - Biolab Sanus Farmaceutica Ltda. - Drawbridge Pharmaceuticals Pty Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Juniper Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Lipicard Technologies Limited - Merck & Co., Inc. - NanoMedex Pharmaceuticals, Inc. - Paion AG - Phosphagenics Limited - Physica Pharma SAS - Proteus SA - Sphaera Pharma Pvt. Ltd. - Taiwan Liposome Company, Ltd. - The Medicines Company For more information visit http://www.researchandmarkets.com/research/25...tic_effect
MRK: 58.79 (+0.36), JNP: 7.60 (+0.08)

PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy
Marketwired - Tue Dec 01, 7:02AM CST
PAION, Inc., a wholly owned subsidiary of PAION AG, today announced the initiation of a smaller dedicated safety study of Remimazolam in ASA III/IV patients (American Society of Anesthesiologists classification III to IV) undergoing colonoscopy as part of the U.S. Phase III program. This trial will run alongside the two ongoing pivotal U.S. Phase III trials in colonoscopy and bronchoscopy.

Remimazolam Posters at Anesthesiology(R) 2015
Marketwired - Mon Oct 12, 7:01AM CDT
PAION, Inc., a wholly owned subsidiary of PAION AG (XETRA: PA8), today announced its presence (booth 2315) and the presentation of results so far generated in the completed clinical trials in general anesthesia with Remimazolam at Anesthesiology® 2015.

Sedation - Pipeline Review, H2 2015
M2 - Fri Sep 04, 4:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wn8rs9/sedation) has announced the addition of the "Sedation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sedation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sedation and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to Buy The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Advicenne Pharma - AstraZeneca Plc - Concert Pharmaceuticals - Drawbridge Pharmaceuticals - Jiangsu Nhwa Pharma Corporation - NanoMedex Pharmaceuticals - Paion AG - The Medicines Company For more information visit http://www.researchandmarkets.com/research/wn8rs9/sedation
AZN: 33.58 (-0.71), CNCE: 11.49 (-0.28)

Timothy E. Morris Joins PAION Inc. As A Non Executive Director
PR Newswire - Fri Aug 07, 7:00AM CDT
PAION, Inc., a wholly owned subsidiary of PAION AG, today announced the appointment of Timothy E. Morris to the non executive Board of PAION, Inc. where he will also serve as a financial advisor to the company. Tim Morris has 31 years of professional finance and accounting experience, 20 of those years spent in the role of Chief Financial Officer, predominantly with biopharmaceutical companies. Tim Morris will advise PAION Inc. on the financing of the company's growing U.S. activities and in preparing for the upcoming commercialisation of Remimazolam.

PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy
PR Newswire - Mon Jun 08, 7:00AM CDT
PAION, Inc., a wholly owned subsidiary of PAION AG, today announced the initiation of the second pivotal U.S. Phase 3 clinical trial of Remimazolam, an ultra-short-acting sedative/anesthetic, for procedural sedation in patients undergoing bronchoscopy.

David Bernstein, M.D. Joins PAION As Medical Advisor & Non Executive Director Of PAION Inc
PR Newswire - Thu May 07, 7:00AM CDT
PAION, Inc., a wholly owned subsidiary of PAION AG, is pleased to announce today that David Bernstein, M.D. has agreed to become PAION's Medical Advisor. In this role, Dr. Bernstein will participate in building the company's U.S. relationships with the academic community, regulators, associations and industry. He will also play an active role in the growth of the company's value proposition, with a special focus on the U.S.

PAION Founds USA Based Subsidiary and Engages an Experienced U.S. Industry Expert as CEO
Marketwired - Mon Oct 27, 7:04AM CDT
PAION AG, a Specialty Pharma Company (ISIN DE000A0B65S3) (XETRA: PA8) will increase its presence in the North American market with the formation of the US-subsidiary PAION Inc. The new company has been established recently and will now start the operational activities under the leadership of Greg Papaz, who will be reporting to Wolfgang Söhngen, CEO of PAION AG and Chairman of the new entity. The office will be located in New Jersey.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 0

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Daqo New Energy Faces Key Investor Meeting in December

Updated Category News Views 88

Spotlight on December's Agenda for Daqo Shareholders Who'd have thought we'd be looking at another year end with the same burning energy interests? Daqo New Energy Corp. (NYSE: DQ) is setting up for its annual general meeting (AGM) dated December 10, 2026. Mark your calendars, because these gatherings can be more than just straightforward affairs; sometimes they reveal...

Continue Reading
Asia-Pacific Miracle: New Economic Chapter Unfolds

Updated Category News Views 44

A Fresh Breeze in Asia-Pacific's Sails You ever look around and realize everything's about to change—again? That's Asia-Pacific right now. We're staring down the barrel of a new chapter in what folks are calling the "Asia-Pacific miracle." The text from China Daily paints a picture of a region gearing up to crank the cooperation dial even higher. And where's this...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 74

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 165

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
PepsiCo Nears Deforestation-Free Sourcing Milestone by 2025

Updated Category News Views 34

PepsiCo's Aim for a Greener Supply Chain Well, look who's climbing the environmental ladder—PepsiCo. They’ve apparently hit 94% deforestation-free sourcing for those high-stakes commodities their empire relies on. Maybe it's a wake-up call for the rest of 'em still smogging about. The endgame? Full-fledged deforestation-free sourcing by 2030. That’s no walk in the...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 159

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 57

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 77

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 42

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading

Top 5 Most Recently Viewed Articles

Swinerton Strengthens Leadership in Design-Build Initiatives

Updated Category News Views 250

Swinerton Welcomes Jason Bone as New Design-Build Leader In an exciting development, Swinerton Incorporated has bolstered its design-build leadership by appointing Jason Bone as the Director of National Design-Build. With this strategic move, the company reaffirms its dedication to providing exceptional client experiences while adapting to the evolving demands of the...

Continue Reading
PayPoint plc Announces PDMR Shareholding Updates

Updated Category News Views 144

PayPoint plc PDMR Share Acquisitions The company, PayPoint plc, recently shared exciting news regarding the shareholdings of its key executives, known as Persons Discharging Managerial Responsibilities (PDMRs). These PDMRs are significant players in the company, including its Executive Directors, and they participate in the Share Incentive Plan (SIP) designed to encourage...

Continue Reading
UMH Properties Announces First Quarter 2025 Financial Insights

Updated Category News Views 349

UMH Properties Reports Strong First Quarter Results for 2025 UMH Properties, Inc. (NYSE: UMH) recently revealed its financial results for the first quarter of 2025, showcasing encouraging growth and improvement in various operational metrics. The company reported a total income of $61.2 million for the quarter ending March 31, 2025, reflecting a 6% increase compared to...

Continue Reading
Netcompany Group Launches Share Buyback to Enhance Value

Updated Category News Views 245

Share Buyback Program Update from Netcompany Group Company announcement No. 20/2025 1 September 2025 On 14 August 2025, Netcompany Group A/S announced the initiation of a share buyback program of up to DKK 500 million, aiming to repurchase a total of 3,700,000 shares. This strategic move is designed to adjust the company’s capital structure while also fulfilling...

Continue Reading
Marex Group Investors: Join the Securities Fraud Class Action

Updated Category News Views 190

Recent Class Action Notice for Marex Group plc Investors In a significant announcement, a class action lawsuit has been filed that could impact many investors in Marex Group plc (NASDAQ: MRX). This legal action arises from reports that raise serious allegations regarding the company's financial reporting practices. For those who bought Marex shares, this is a crucial time...

Continue Reading